HOOK - HOOKIPA Pharma GAAP EPS of -$0.65 misses by $0.03 revenue of $3.9M beats by $0.11M
HOOKIPA Pharma press release (NASDAQ:HOOK): Q4 GAAP EPS of -$0.65 misses by $0.03. Revenue of $3.9M (-24.4% Y/Y) beats by $0.11M. The company expects to file an Investigational New Drug (IND) application for HB-300 in the third quarter of 2022. CEO comment: “With the recent capital raise from new and existing top-tier investors, as well as funding from our Gilead collaboration, our cash position provides funding into the first half of 2024, enabling us to advance our novel portfolio."
For further details see:
HOOKIPA Pharma GAAP EPS of -$0.65 misses by $0.03, revenue of $3.9M beats by $0.11M